Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Reimportation Could Help PBMs Reduce Costs, Caremark SEC Filing Says

Executive Summary

Caremark expects pharmacy benefit managers to benefit from prescription drug reimportation, the company's Securities & Exchange Commission filing regarding its proposed merger with AdvancePCS states

You may also be interested in...

Caremark/AdvancePCS Merger Will Give Company Half Medco’s Mail Capacity

Caremark will have about half of Medco's mail-order prescription capacity following the proposed acquisition of AdvancePCS

Retail Pharmacy Class Actions Versus PBMs Challenge “No Mail” Clauses

Medco's standard "no mail" clause in its retail pharmacy contracts is one practice that pharmacies are hoping to change through a class action suit filed in Philadelphia federal court

Rx Reimportation Passes House; CBO Score May Keep It Out Of Medicare Rx

The Congressional Budget Office's determination that prescription drug reimportation would not provide any cost savings could help House/Senate Medicare conferees distance themselves from the House's positive vote on reimportation

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts